GB201604494D0 - Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers - Google Patents

Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers

Info

Publication number
GB201604494D0
GB201604494D0 GBGB1604494.3A GB201604494A GB201604494D0 GB 201604494 D0 GB201604494 D0 GB 201604494D0 GB 201604494 A GB201604494 A GB 201604494A GB 201604494 D0 GB201604494 D0 GB 201604494D0
Authority
GB
United Kingdom
Prior art keywords
transfected
cells
cell receptors
immunotherapy against
against cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1604494.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1604494.3A priority Critical patent/GB201604494D0/en
Publication of GB201604494D0 publication Critical patent/GB201604494D0/en
Priority to IL261787A priority patent/IL261787B2/en
Priority to JP2018548050A priority patent/JP6929867B2/ja
Priority to HUE17710963A priority patent/HUE060725T2/hu
Priority to AU2017235069A priority patent/AU2017235069B2/en
Priority to MYPI2018703734A priority patent/MY193474A/en
Priority to MX2018011223A priority patent/MX2018011223A/es
Priority to CN201780017419.XA priority patent/CN108884143A/zh
Priority to TW106108697A priority patent/TWI788284B/zh
Priority to EP17710963.4A priority patent/EP3430037B1/en
Priority to DK17710963.4T priority patent/DK3430037T3/da
Priority to PT177109634T priority patent/PT3430037T/pt
Priority to RS20221044A priority patent/RS63727B1/sr
Priority to US15/461,020 priority patent/US10537624B2/en
Priority to SG11201807590SA priority patent/SG11201807590SA/en
Priority to UAA201809121A priority patent/UA124532C2/uk
Priority to CA3017419A priority patent/CA3017419A1/en
Priority to MA43328A priority patent/MA43328B2/fr
Priority to MDE20190102T priority patent/MD3430037T2/ro
Priority to NZ746387A priority patent/NZ746387A/en
Priority to LTEPPCT/EP2017/056289T priority patent/LT3430037T/lt
Priority to EA201891759A priority patent/EA201891759A1/ru
Priority to BR112018067989-5A priority patent/BR112018067989A2/pt
Priority to PCT/EP2017/056289 priority patent/WO2017158116A1/en
Priority to CR20180490A priority patent/CR20180490A/es
Priority to PE2018001777A priority patent/PE20190124A1/es
Priority to KR1020187029658A priority patent/KR102266721B1/ko
Priority to ES17710963T priority patent/ES2930681T3/es
Priority to MA45309A priority patent/MA45309B1/fr
Priority to HRP20221375TT priority patent/HRP20221375T1/hr
Priority to PL17710963.4T priority patent/PL3430037T3/pl
Priority to EP22192967.2A priority patent/EP4177264A1/en
Priority to PH12018501892A priority patent/PH12018501892A1/en
Priority to CL2018002610A priority patent/CL2018002610A1/es
Priority to CONC2018/0010808A priority patent/CO2018010808A2/es
Priority to US16/413,939 priority patent/US10596242B2/en
Priority to US16/802,431 priority patent/US11730796B2/en
Priority to US18/343,502 priority patent/US20230321208A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
GBGB1604494.3A 2016-03-16 2016-03-16 Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers Ceased GB201604494D0 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
GBGB1604494.3A GB201604494D0 (en) 2016-03-16 2016-03-16 Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
EP22192967.2A EP4177264A1 (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
MDE20190102T MD3430037T2 (ro) 2016-03-16 2017-03-16 Celule T transfectate și receptori de celule T pentru utilizare în imunoterapie împotriva cancerelor
NZ746387A NZ746387A (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
HUE17710963A HUE060725T2 (hu) 2016-03-16 2017-03-16 Transzfektált T-sejtek és T-sejt receptorok daganatok ellen alkalmazott immunterápiában történõ használatra
AU2017235069A AU2017235069B2 (en) 2016-03-16 2017-03-16 Transfected T-cells and T-cell receptors for use in immunotherapy against cancers
MYPI2018703734A MY193474A (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
MX2018011223A MX2018011223A (es) 2016-03-16 2017-03-16 Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer.
CN201780017419.XA CN108884143A (zh) 2016-03-16 2017-03-16 用于癌症免疫治疗的转染t细胞和t细胞受体
TW106108697A TWI788284B (zh) 2016-03-16 2017-03-16 用於抗癌免疫治療的轉染t細胞及t細胞受體
EP17710963.4A EP3430037B1 (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
EA201891759A EA201891759A1 (ru) 2016-03-16 2017-03-16 Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
PT177109634T PT3430037T (pt) 2016-03-16 2017-03-16 Células t transfetadas e recetores de células t para uso em imunoterapia anticancro
RS20221044A RS63727B1 (sr) 2016-03-16 2017-03-16 Transficirane t ćelije i t-ćelijski receptori za upotrebu u imunoterapiji protiv malignih tumora
US15/461,020 US10537624B2 (en) 2016-03-16 2017-03-16 Transfected T-cells and T-cell receptors for use in immunotherapy against cancers
SG11201807590SA SG11201807590SA (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
UAA201809121A UA124532C2 (uk) 2016-03-16 2017-03-16 Т-клітинний рецептор для лікування раку
CA3017419A CA3017419A1 (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
MA43328A MA43328B2 (fr) 2016-03-16 2017-03-16 Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
IL261787A IL261787B2 (en) 2016-03-16 2017-03-16 Nucleic acid-treated t-cells and receptor t-cells for use in immunotherapy against types of cancer
LTEPPCT/EP2017/056289T LT3430037T (lt) 2016-03-16 2017-03-16 Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją
JP2018548050A JP6929867B2 (ja) 2016-03-16 2017-03-16 がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体
DK17710963.4T DK3430037T3 (da) 2016-03-16 2017-03-16 Transficerede t-celler og t-cellereceptorer til anvendelse i immunterapi mod cancere
BR112018067989-5A BR112018067989A2 (pt) 2016-03-16 2017-03-16 células t transfectadas e receptores de células t para uso em imunoterapia anticâncer
PCT/EP2017/056289 WO2017158116A1 (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CR20180490A CR20180490A (es) 2016-03-16 2017-03-16 Celulas t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer
PE2018001777A PE20190124A1 (es) 2016-03-16 2017-03-16 Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer
KR1020187029658A KR102266721B1 (ko) 2016-03-16 2017-03-16 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체
ES17710963T ES2930681T3 (es) 2016-03-16 2017-03-16 Linfocitos T transfectados y receptores de linfocito T para el uso en la inmunoterapia contra el cáncer
MA45309A MA45309B1 (fr) 2016-03-16 2017-03-16 Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
HRP20221375TT HRP20221375T1 (hr) 2016-03-16 2017-03-16 Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka
PL17710963.4T PL3430037T3 (pl) 2016-03-16 2017-03-16 Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
PH12018501892A PH12018501892A1 (en) 2016-03-16 2018-09-05 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CL2018002610A CL2018002610A1 (es) 2016-03-16 2018-09-12 Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer
CONC2018/0010808A CO2018010808A2 (es) 2016-03-16 2018-10-09 Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer
US16/413,939 US10596242B2 (en) 2016-03-16 2019-05-16 Transfected T-cells and T-cell receptors for use in immunotherapy against cancers
US16/802,431 US11730796B2 (en) 2016-03-16 2020-02-26 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
US18/343,502 US20230321208A1 (en) 2016-03-16 2023-06-28 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1604494.3A GB201604494D0 (en) 2016-03-16 2016-03-16 Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers

Publications (1)

Publication Number Publication Date
GB201604494D0 true GB201604494D0 (en) 2016-04-27

Family

ID=55952419

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1604494.3A Ceased GB201604494D0 (en) 2016-03-16 2016-03-16 Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers

Country Status (18)

Country Link
US (1) US10537624B2 (https=)
EP (1) EP3430037B1 (https=)
JP (1) JP6929867B2 (https=)
KR (1) KR102266721B1 (https=)
CN (1) CN108884143A (https=)
AU (1) AU2017235069B2 (https=)
BR (1) BR112018067989A2 (https=)
CA (1) CA3017419A1 (https=)
CR (1) CR20180490A (https=)
EA (1) EA201891759A1 (https=)
GB (1) GB201604494D0 (https=)
MA (2) MA45309B1 (https=)
MX (1) MX2018011223A (https=)
PE (1) PE20190124A1 (https=)
SG (1) SG11201807590SA (https=)
TW (1) TWI788284B (https=)
UA (1) UA124532C2 (https=)
WO (1) WO2017158116A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
NZ746387A (en) * 2016-03-16 2022-08-26 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
TW201835100A (zh) * 2017-02-06 2018-10-01 國立研究開發法人國立癌症研究中心 新穎ｔ細胞受體
JP2020537515A (ja) 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
WO2019157454A1 (en) 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
AU2019218397A1 (en) * 2018-02-12 2020-10-01 Fred Hutchinson Cancer Center Cyclin A1 specific T cell receptors and uses thereof
US12331095B2 (en) 2018-03-14 2025-06-17 Medigene Immunotherapies Gmbh Inducible T cell receptors and uses thereof
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
EP3773908A1 (en) * 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
US12275773B2 (en) 2018-09-21 2025-04-15 Xlifesc, Ltd. High affinity cell receptor for recognizing AFP antigen
WO2020123388A1 (en) * 2018-12-11 2020-06-18 Board Of Regents, The University Of Texas System Radiotherapies and uses thereof
WO2020127827A1 (de) * 2018-12-20 2020-06-25 Ava Lifescience Gmbh Verfahren zur selektion biologischer bindemoleküle
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
CA3144054A1 (en) * 2019-06-20 2020-12-24 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
CN110357953B (zh) * 2019-07-17 2022-05-03 深圳市因诺转化医学研究院 识别人巨细胞病毒pp65抗原的TCR
EP4003375A4 (en) * 2019-07-31 2023-09-06 Forty Seven, Inc. DEPLETION DIETS FOR MODIFIED T CELL OR NK CELL THERAPY
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
MX2022002984A (es) * 2019-09-12 2022-06-16 Tcr2 Therapeutics Inc Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20230226181A1 (en) * 2020-06-22 2023-07-20 Nanjing Legend Biotech Co., Ltd. GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPY
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
AU2014271235B2 (en) * 2008-10-01 2017-03-02 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
TW201124530A (en) 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
KR102480188B1 (ko) * 2012-09-14 2022-12-21 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors

Also Published As

Publication number Publication date
JP6929867B2 (ja) 2021-09-01
EP3430037B1 (en) 2022-08-31
UA124532C2 (uk) 2021-10-05
TW201742873A (zh) 2017-12-16
PE20190124A1 (es) 2019-01-17
CN108884143A (zh) 2018-11-23
WO2017158116A1 (en) 2017-09-21
MA45309A (fr) 2019-01-23
KR20180122430A (ko) 2018-11-12
MX2018011223A (es) 2018-11-22
EP3430037A1 (en) 2019-01-23
CA3017419A1 (en) 2017-09-21
JP2019512242A (ja) 2019-05-16
US10537624B2 (en) 2020-01-21
US20170312350A1 (en) 2017-11-02
MA43328B2 (fr) 2022-02-28
MA45309B1 (fr) 2023-01-31
AU2017235069A1 (en) 2018-10-04
AU2017235069B2 (en) 2020-05-07
EA201891759A1 (ru) 2019-02-28
MA43328A1 (fr) 2019-05-31
BR112018067989A2 (pt) 2019-02-05
KR102266721B1 (ko) 2021-06-17
SG11201807590SA (en) 2018-10-30
TWI788284B (zh) 2023-01-01
CR20180490A (es) 2019-01-10

Similar Documents

Publication Publication Date Title
IL261788A (en) Nucleic acid-treated t-cells and receptor t-cells for use in immunotherapy against types of cancer
GB201604492D0 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604494D0 (en) Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
HUE060725T2 (hu) Transzfektált T-sejtek és T-sejt receptorok daganatok ellen alkalmazott immunterápiában történõ használatra
IL269578A (en) T cell receptors and immune therapy using the same against prame positive cancers
IL266511A (en) A long-acting il-2 beta receptor agonist in combination with a vaccine for use in cancer therapy
ZA201808623B (en) Glucocorticoid receptor agonist and immunoconjugates thereof
IL289866A (en) Sting antibody-agonist conjugates and their use in immunotherapy
SG11202103609YA (en) T-cell receptors and uses thereof
SG10202007962RA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
GB201604458D0 (en) Peptides and combination of peptides for use in immunotherapy against cancers
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
PL3551221T3 (pl) Nowe receptory komórek t i immunoterapia z ich zastosowaniem
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
SG11201606898TA (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
GB201511546D0 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202107869QA (en) Peptides and combination thereof for use in the immunotherapy against cancers
GB201604490D0 (en) Peptides combination of peptides for use in immunotherapy against cancers
GB201520191D0 (en) T-cell receptor and uses thereof
SG10202100326SA (en) Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
SG11202009442YA (en) Peptides for use in immunotherapy against cancers
IL282926A (en) T cell receptors specific for mesothelin and their use in immunotherapy
IL279621A (en) Cancer-specific T-cell receptors
GB201719169D0 (en) Novel T-cell receptor and ligand
IL264855B1 (en) T cell receptors and immune therapy using the same

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)